Skip to main
BDTX

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is positioned for significant growth due to multiple anticipated catalysts, which could potentially lead to a substantial increase in stock value. The company's focus on actionable mutations, with drugs like silevertinib demonstrating strong clinical efficacy—including a 60% confirmed overall response rate—supports a favorable outlook for market opportunities, particularly in the lucrative first-line non-small cell lung cancer (NSCLC) segment. Additionally, expected forecasted sales of approximately $500-750 million for their pipeline therapies, compared to the M&A valuations of similar-sized oncology firms, suggests a compelling upside potential for investors.

Bears say

The analysis of Black Diamond Therapeutics Inc reveals concerns regarding the effectiveness and competitive positioning of its drug candidates, particularly silevertinib, which has exhibited lower objective response rates (ORR) compared to competitors in similar clinical settings. The company’s reliance on a lower dosage has raised doubts about the replicability of its reported 60% ORR and overall confidence in its pipeline, leading to a lack of investor confidence reflected in its market capitalization of approximately $230 million. Additionally, the risk associated with varying patient populations and mutation types in ongoing trials may further limit the therapeutic potential and market traction of silevertinib, creating an unfavorable outlook for the company’s stock performance.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.